Haemostatix

Haemostatix, a spin out from Leicester University, has developed a new technology platform with potential applications in both topical and systemic control of bleeding.

Haemostatix's lead product, PeproStat^TM, is based on a short peptide that binds to the protein fibrinogen in blood to form a fibrin-like clot. This mode of action is novel and fast acting. The components of PeproStat are stable, enabling  the formulation of ready-to-use liquid and flowable gel products. PeproStat will meet the needs of surgeons for a fast, effective, safe and convenient haemostat.